TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
Transcenta, Biologics, Antibody, Claudin 18.2
While striving to build its own R&D strength, Transcenta has established and continues to explore collaborations with biotech/pharmaceutical companies and research institutions worldwide. If you want to share a partnership or technology opportunity with Transcenta, please submit your non-confidential information here for review.
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. The company has made advancements in oncology, hematology, immunology and cardiovascular disease, and is dedicated to helping patients prevail over serious diseases through its diverse and promising pipeline.
Eli Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund was founded in Shanghai in early 2018, as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures. Supported by numerous renowned institutional investors specialized in the biopharmaceutical industry, Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Alehund’s pipeline comprises both small-molecule and biologic assets.
Merck , a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
IQVIA is an American multinational company serving the combined industries of health information technologies and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services. It committed to providing solutions that enable life sciences companies to innovate with confidence, maximize opportunities, and, ultimately, drive human health outcomes forward.
Covance is a leading contract research organization (CRO) that provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Covance provide comprehensive drug development solutions and are on a mission to advance health and power clear, confident decisions.
Beijing Cancer Hospital was founded in 1976 and is co-administered by Peking University and Beijing Hospitals Authority. It is a tertiary A-level hospital specializing in cancer treatment, research, prevention, and medical education. Since its establishment, the hospital has been dedicated to diagnosis, comprehensive treatment and translational research regarding gastric cancer, breast cancer, lung cancer, colorectal cancer, liver cancer, esophageal cancer, malignant lymphoma, malignant melanoma, urinary system tumors, gynecological tumors, head and neck tumors, bone tumors, sarcomas, etc. Its research on gastric cancer prevention and treatment system has won the second prize of National Science and Technology Progress Award twice.
Dana-Farber Cancer Institute in Boston, Massachusetts was founded in 1947, has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research.
Shanghai Pulmonary Hospital , established in 1933, is a state-of-the-art tertiary A-level specialized teaching hospital that combines medical, teaching, and scientific research functions. The hospital specializes in the comprehensive treatment of lung cancer, diagnosis and treatment of difficult lung diseases, tuberculosis prevention and control, occupational disease prevention and control, and other related diseases.
Shanghai Jiao Tong University (SJTU) , as one of the higher education institutions which enjoy a long history and a world-renowned reputation in China, is a key university directly under the administration of the Ministry of Education (MOE) of the People's Republic of China and co-constructed by MOE and Shanghai Municipal Government. Through some 120 years' unremitting efforts, SJTU has become a comprehensive, research-oriented, and internationalized top university in China.
Yale Since its founding in 1701,has been dedicated to expanding and sharing knowledge, inspiring innovation, and preserving cultural and scientific information for future generations. Yale’s reach is both local and international. It partners with its hometown of New Haven, Connecticut to strengthen the city’s community and economy. And it engages with people and institutions across the globe in the quest to promote cultural understanding, improve the human condition, delve more deeply into the secrets of the universe, and train the next generation of world leaders.
G-CON Manufacturing designs, produces and installs prefabricated, autonomous cleanroom PODs®. G-CON's cleanroom POD® portfolio encompasses a variety of different dimensions and purposes, from laboratory environments to personalized medicine and production process platforms.
908 Devices is setting off a revolution in how chemical analysis gets done. We offer point-of-need chemical and biomolecular analysis devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. These purpose-built and user-centric devices serve the life science, field forensics and other applied markets. 908 Devices is headquartered in the heart of Boston where we research, design and manufacture innovative products based on high-pressure mass spectrometryTM (HPMS) and microfluidic separation technology.
Inhibrx’s mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, Inhibrx has built a large and diverse pipeline with the potential to impact cancer, infectious disease and orphan diseases.